Interesting report via the @cfr.org and @tombollyky.bsky.social launched today:
"U.S. dependence on China for essential medicines is structural...That dependence is not simply the result of market conditions but rather decades of Chinese state investment."
www.cfr.org/reports/the-...
Our very own Dr. Paul Bollyky (far right) has been elected to the Association of American Physicians (AAP), one of academic medicine's highest honors. Congrats to him and colleague Nigam Shah, celebrated at the AAP Induction Dinner the past weekend!
SCIENCE, SUPPLY CHAINS, GEOECONOMICS, AND POLICY INCENTIVES
The Pharma Choke Point: How to Reduce U.S. Dependence on Chinese Pharmaceutical and Biotechnology Supply Chains
Important new study from @tombollyky.bsky.social, @rushdoshi.bsky.social, @prof-yadav.bsky.social & Olivia Kosloff
🚨NEW @trade--talks.bsky.social episode!!
@tombollyky.bsky.social joined @chadpbown.com to explain the problems facing the US pharma market, Trump's new 100% tariffs & pricing deal with the UK, & impact on American drug prices & supply chain security.
Here or wherever you get podcasts:
Spent last year deep in supply chain security for my book—pharma near the top of the list for policymakers globally. Excited to dig into Trump's latest tariff announcement with @tombollyky.bsky.social, one of the leading voices on trade, security, and public health.
The new America First Global Health Strategy goes back to the future
Meaning, the strategy is a seriously regressive one
@tombollyky.bsky.social
www.thelancet.com/journals/lan...
A new report by @cfr.org @tombollyky.bsky.social @rushdoshi.bsky.social @prof-yadav.bsky.social , Olivia Kosloff & Elena Every on the risks of China weaponizing pharma supply chains as a tool of economic or political coercion.
www.cfr.org/reports/the-...
Of the $3.6 billion contributed to UN’s Ebola Response Fund in West Africa epidemic, China gave $47 million(~1%) while United States donated $1.8 billion(49%)
They are doing even less now
The greatest risk to Americans isn't China will supplant US as leader in global health. It's that no one will
"The new America First Global Health Strategy"
Check out the lede
Yet "The world still faces dire health threats that countries
cannot fight alone"
www.thelancet.com/journals/lan... @thelancet.com by @tombollyky.bsky.social
Secretary Kennedy’s Senate hearing illustrated that the United States’ scientific reputation—long considered a global gold standard—is at risk of eroding. @tombollyky.bsky.social writes: "There is no question that the events of the last week have put the health and lives of Americans at risk."
The U.S. pharmaceutical supply chain faces a threat equal to the rare-earths challenge already posed by China’s exploitation of its dominance of those critical minerals. The authors provide a model th...
Thomas J. Bollyky (CFR) joins to explain the pricing and supply chain implications of Trump’s new tariffs on pharmaceutical products as well as the US-UK deal.
tradetalkspodcast.com
The U.S. pharmaceutical supply chain faces a threat equal to the rare-earths challenge already posed by China’s exploitation of its dominance of those critical minerals. The authors provide a model th...
After months of effectively dismantling the architecture of US global health engagement
by closing the US Agency for International Development, reducing its annual global
health awards by an estimated...
The U.S. pharmaceutical supply chain faces a threat equal to the rare-earths challenge already posed by China’s exploitation of its dominance of those critical minerals. The authors provide a model th...
Secretary Kennedy’s Senate hearing on Thursday illustrated that the United States’ scientific reputation—long considered a global gold standard—is at risk of eroding.
NEW EPISODE: @tombollyky.bsky.social joins to explain the problems facing the US pharmaceutical market, Trump's new 100% tariffs and pricing deal with the United Kingdom, and the impact on American drug prices as well as supply chain security.
“As Ebola spreads in East Africa, the United States is playing a much smaller role than it has in previous outbreaks. That leaves China, an economic powerhouse with epidemic control and biotech expertise, as the next global power that could commit supplies, money and medical workers to the effort”
Thomas J. Bollyky (CFR) joins to explain the pricing and supply chain implications of Trump’s new tariffs on pharmaceutical products as well as the US-UK deal.
